No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CLDX240517P15000
- 0.18
- 0.000.00%
15min DelayClose Nov 6 12:49 ET
0.00High0.00Low
0.00Open0.18Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover6537.82%IV-59.20%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-5DDays to Expiry0.18Time Value100Contract SizeAmericanOptions Type-0.0202Delta0.0024Gamma201.78Leverage Ratio-19.7534Theta0.0000Rho-4.09Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
Express News | Celldex Doses First Patient In Phase 2 Study Of Barzolvolimab In Prurigo Nodularis
Express News | Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
We're Interested To See How Celldex Therapeutics (NASDAQ:CLDX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Celldex Therapeutics: A Strong Buy on Impressive Barzolvolimab Results and Promising Pipeline
Unveiling 4 Analyst Insights On Celldex Therapeutics
In the latest quarter, 4 analysts provided ratings for Celldex Therapeutics (NASDAQ:CLDX), showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings, o
Express News | Celldex Therapeutics Inc - Cash, Cash Equivalents and Marketable Securities as of March 31, 2024 Were $823.8 Mln
Comments
$Celldex Therapeutics(CLDX.US$
$Arrowhead Pharmaceuticals(ARWR.US$ - Alpha Early Alert 🚨 H&S 📈🎯🚀🥇 (45.00) is on the Table 🫵🏻💪🏻🥇 Find the Apex and win!
$Arrowhead Pharmaceuticals(ARWR.US$ - Alpha Early Alert 🚨 H&S 📈🎯🚀🥇 (45.00) is on the Table 🫵🏻💪🏻🥇 Find the Apex and win!
1
Gainers:
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
• $Cytokinetics(CYTK.US$ +8.7% (prices offering of of $450.0 mln of 3.50% convertible senior notes due 2027)
• $XPeng(XPEV.US$ +3.4% (June deliveries)
• $NIO Inc(NIO.US$ +2.9% (June deliveries)
• $Bitfarms(BITF.US$ +2.7% (provides June 2022 production and mining operations update)
• $Accolade(ACCD.US$ +2.7% (In reaction to earnings/guidance)
• $BioCryst Pharmaceuticals(BCRX.US$ +2.6% (presents new data demonstrating...
18
1
2
Read more